Melanotan II

Melanotan II is a synthetic α-MSH analogue that activates multiple melanocortin receptors to stimulate melanin production, enhance sexual arousal, and support metabolic activity. Commonly studied in research for skin pigmentation, libido modulation, and energy regulation.

$49.00

Add to Wishlist

For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.

Category:

Description

Melanotan II (Ac-Nle-Cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It functions as a broad-spectrum melanocortin receptor agonist, activating multiple receptors (MC1R–MC5R) to provide effects across pigmentation, sexual function, and metabolism.

Mechanism of Action

  • MC1R Activation: Stimulates melanocytes to increase melanin production for natural skin tanning

  • MC3R / MC4R Activation: Enhances sexual arousal and libido via hypothalamic pathways

  • MC5R Activation: Supports fat metabolism and energy utilization

  • Provides a multi-domain effect: improved skin tone, sexual vitality, and metabolic drive

Dosage Guidelines (Research Use)

  • Initial Loading Phase: 0.25–0.5 mg per day for 5–10 days or until desired pigmentation is achieved

  • Maintenance Phase: 0.5–1 mg per week, divided into one or two injections to maintain pigmentation

  • Administration Notes: Start with a lower dose to monitor tolerance; adjust based on response

  • Mild side effects may include nausea, flushing, and temporary changes in libido

  • Rarely, unnatural pigmentation may occur in some individuals

Useful Information

  • Class: Synthetic α-MSH analogue / broad-spectrum melanocortin receptor agonist

  • Category: Cosmetic & Sexual Health Peptides

  • Primary Research Focus: Skin tanning, sexual function, metabolic support

Reviews

There are no reviews yet.

Be the first to review “Melanotan II”

Your email address will not be published. Required fields are marked *